EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic profiling of drug resistance markers in Plasmodium falciparum samples from the Democratic Republic of the Congo (2017) and Tanzania (2020–2021)

Flory Luzolo Khote iD, Hypolite Muhindo Mavoko, Patrick Mitashi, Papy Mandoko, Destin Mbongi, Geofrey Makenga, Daniel T R Minja, Filbert Francis, Reginald Kavishe, Jean-Pierre van Geertruyden, Gauthier Mesia Kahunu, Didier Menard und 1 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Flory Luzolo Khote und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tropical Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo. Hauptthemen laut MEDLINE: Plasmodium falciparum, Drug Resistance, Antimalarials, Malaria, Falciparum. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EDCTP Career Development Fellowship, French Government (Agence Nationale de la Recherche), Laboratoire d'Excellence (LabEx) 'French Parasitology Alliance for Health Care'.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular surveillance is essential to detect emerging artemisinin partial resistance (ART-R) and partner drug resistance in Sub-Saharan Africa.

Objectives

To describe the prevalence of Plasmodium falciparum resistance markers in two high-burden countries using artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL): the Democratic Republic of the Congo (DRC) and Tanzania.

Methods

A total of 1254 day-0 P. falciparum-positive samples were analysed: 837 from four sentinel sites of a therapeutic efficacy study (TES) in the DRC (2017) and 417 from an intermittent preventive treatment in schoolchildren (IPTsc) trial in Handeni and Kilindi districts, Tanga Region, Tanzania (2020–2021). Pfkelch13, Pfcrt and Pfmdr1 were analysed by Illumina MiSeq amplicon sequencing.

Results

Reliable sequences were obtained for 1193 isolates. The Pfkelch13 wild-type allele predominated (98.4%); none of the four non-synonymous mutations detected (N489Y, K568T, A578S, V589I) are classified as validated, candidate or potential ART-R markers, and the validated markers R561H, P441L and C469Y reported elsewhere in East Africa were absent. Pfcrt K76T was found in 23.3% of Tanzanian and 26.3% of DRC isolates, with substantial between-site variation in the DRC (4.3% to 93.6% at Rutshuru). Pfmdr1 haplotype profiles differed between countries: NFSND predominated in Tanzania (71.5%) while NYSND remained the most frequent in the DRC (60.9%); 86Y was twice as frequent in the DRC (11.1%) as in Tanzania (6.2%).

Conclusions

No validated ART-R marker was detected, but partner-drug haplotype distributions reflected the first-line ACTs used in each country. Continued molecular surveillance is needed to track these signatures alongside the recent emergence of ART-R.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumDrug ResistanceAntimalarialsMalaria, FalciparumTanzaniaHumansDemocratic Republic of the CongoProtozoan ProteinsAmodiaquineDrug CombinationsArtemisininsArtemether, Lumefantrine Drug CombinationATP-Binding Cassette, Sub-Family C Proteins

Substanzen

AntimalarialsProtozoan ProteinsAmodiaquineamodiaquine, artesunate drug combinationDrug CombinationsArtemisininsArtemether, Lumefantrine Drug CombinationATP-Binding Cassette, Sub-Family C Proteins

Autor:innen und Institutionen

  • Department of Tropical Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Global Health Institute, University of Antwerp, Antwerp, Belgium.
  • Departement de parasitologie, Institut National des Recherches Biomédicales (INRB), Kinshasa, Republique Démocratique du Congo.
  • Centre Hospitalier Monkole, Kinshasa, Democratic Republic of the Congo.
  • National Institute for Medical Research, Tanga, Tanzania.
  • Kilimanjaro Clinical Research Institute (KCRI), Kilimanjaro Christian Medical University College (KCMUCo), Tumaini University Makumira, Moshi, Tanzania.

ORCID-Profile: Flory Luzolo Khote

Förderung

  • EDCTP Career Development Fellowship
  • French Government (Agence Nationale de la Recherche)
  • Laboratoire d'Excellence (LabEx) 'French Parasitology Alliance for Health Care'
  • University of Strasbourg
  • Global Fund
  • Laboratoire d’Excellence (LabEx) ‘French Parasitology Alliance for Health Care’

Zitieren

APA

Khote, F. L., Muhindo Mavoko, H., Mitashi, P., Mandoko, P., Mbongi, D., Makenga, G., Minja, D. T. R., Francis, F., Kavishe, R., van Geertruyden, J. P., Kahunu, G. M., Menard, D., & Baraka, V. (2026). Genomic profiling of drug resistance markers in Plasmodium falciparum samples from the Democratic Republic of the Congo (2017) and Tanzania (2020–2021). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag309

Vancouver

Khote FL, Muhindo Mavoko H, Mitashi P, Mandoko P, Mbongi D, Makenga G, et al. Genomic profiling of drug resistance markers in Plasmodium falciparum samples from the Democratic Republic of the Congo (2017) and Tanzania (2020–2021). Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag309

BibTeX
@article{Khote2026,
  author = {Khote, Flory Luzolo and Muhindo Mavoko, Hypolite and Mitashi, Patrick and Mandoko, Papy and Mbongi, Destin and Makenga, Geofrey and Minja, Daniel T R and Francis, Filbert and Kavishe, Reginald and van Geertruyden, Jean-Pierre and Kahunu, Gauthier Mesia and Menard, Didier and Baraka, Vito},
  title = {Genomic profiling of drug resistance markers in Plasmodium falciparum samples from the Democratic Republic of the Congo (2017) and Tanzania (2020–2021)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag309}
}
Kostenlos starten →